ALKS: Revenue grew, guidance held, and orexin programs advanced across neuropsychiatric conditions

What happened

Q3 revenue reached $480.1M, with $16.3M GAAP net income and $120.1M Adjusted EBITDA, and 2026 expectations were reiterated. Orexin programs expanded with ADHD proof-of-concept data and a Phase 2 MDD study start.

Confirmed

Global impact / market context

Revenue growth and held guidance suggest steady business performance, while orexin progress toward ADHD and depression treatments could add future revenue streams. The company is spending on research that may take years to pay off, so profits today depend on existing products.

Analyst inference

Investors weigh near-term earnings against long-term drug pipeline potential. Holding guidance signals management confidence in current forecasts, but new programs remain uncertain. The summary notes possible inaccuracies, so any figures used for investment decisions should come from the original source.

Analyst inference

What to watch

1. Q3 revenue of $480.1M and $16.3M GAAP net income show the current revenue and profit base that funds research spending. Confirmed
2. The Phase 2 MDD study start and ADHD proof-of-concept data are early steps; watch whether future results support continued spending on orexin programs. Proposed
3. If research costs rise before new drugs earn revenue, cash available for operations could tighten, making the reiterated 2026 expectations important to track. Analyst inference

Evidence

• Original source link unavailable